MRKR (Marker Therapeutics) EPS (Basic): $-0.61 (TTM As of Mar. 2026)

What is Marker Therapeutics EPS (Basic)?

Marker Therapeutics MRKR 32 EPS (Basic) is $-0.61 as of Mar. 2026. GuruFocus rates MRKR with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Marker Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.16. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.61.

Marker Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.16. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.61.

Marker Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was $-0.16. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.61.

During the past 3 years, the average EPS without NRI Growth Rate was 31.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 35.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 29.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Marker Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 75.60% per year. The lowest was -66.40% per year. And the median was 36.10% per year.

Marker Therapeutics (NAS:MRKR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Marker Therapeutics EPS (Basic) Related Terms

Marker Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Marker Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marker Therapeutics EPS (Basic) Chart

Marker Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-5.47

-3.58

-0.94

-1.19

-0.79

Marker Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-0.40	-0.29	-0.12	-0.04	-0.16

32GF Score

Marker Therapeutics Inc MRKR

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Marker Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Marker Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-12.164	-	0)	/	15.310
	=	-0.79

Marker Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.179	-	0)	/	19.315
	=	-0.16

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.61

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $-0.61 mean?

Marker Therapeutics (MRKR) has a EPS (Basic) of $-0.61 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Marker Therapeutics and its competitors.

Is Marker Therapeutics' EPS (Basic) too high?

Marker Therapeutics' current EPS (Basic) is $-0.61. Overall, Marker Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Marker Therapeutics' EPS (Basic) compare to OTLC and ALLR?

Marker Therapeutics' EPS (Basic) of $-0.61 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Marker Therapeutics and its competitors. Marker Therapeutics's current EPS (Basic) is $-0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Marker Therapeutics stock overvalued right now?

Marker Therapeutics (MRKR) has a current EPS (Basic) of $-0.61. The current EPS (Basic) is $-0.61. Marker Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Marker Therapeutics (MRKR), the current EPS (Basic) is $-0.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marker Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies OTLC ALLR CLRB PTN SKYE PVCT PLUR VTGN SER KYNB VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges GX1:Germany

Address 2450 Holcombe Boulevard, TMC Partners Office 1.311, Houston, TX, USA, 77021

Website https://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

32GF Score

Get the complete analysis for MRKR

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33

Price

View MRKR Analysis

See EPS (Basic) data for all stocks →